ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Verseau launches with $50 million to develop immunotherapies

by Ryan Cross
October 26, 2019 | APPEARED IN VOLUME 97, ISSUE 42

 

The Bedford, Massachusetts, start-up Verseau Therapeutics has launched with $50 million to develop immunotherapies that target a class of immune cells called macrophages. Existing checkpoint inhibitor therapies help activate T cells to attack some tumors, but the drugs don’t work for everyone. Verseau hopes it can treat more cancers by targeting proteins that can activate macrophages. Many of the firm’s lead programs are antibodies, but it also has licensed lipid nanoparticles from Bob Langer and Dan Anderson’s labs at the Massachusetts Institute of Technology to deliver silencing RNA therapies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment